

Germ Line-governed Recognition of a Cancer Epitope by an Immunodominant Human T-cell Receptor*

Received for publication, March 26, 2009, and in revised form, May 18, 2009. Published, JBC Papers in Press, July 15, 2009, DOI 10.1074/jbc.M109.022509

David K. Cole^{†1,2}, Fang Yuan^{§1}, Pierre J. Rizkallah^{¶¶1}, John J. Miles^{¶¶3}, Emma Gostick[‡], David A. Price^{†4}, George F. Gao^{**}, Bent K. Jakobsen^{††}, and Andrew K. Sewell^{†5}

From the [†]Department of Infection, Immunity, and Biochemistry, Henry Wellcome Building, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, United Kingdom, the [§]Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford University, Oxford OX3 9DU, United Kingdom, the ^{¶¶}STFC Daresbury Laboratory, Warrington, Cheshire WA4 4AD, United Kingdom, the ^{||}Cellular Immunology Laboratory, Queensland Institute of Medical Research, University of Queensland, Brisbane 4029, Australia, the ^{**}Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China, and ^{††}Immunocore Limited, 57C Milton Park, Abingdon, Oxon OX14 4RX, United Kingdom

CD8⁺ T-cells specific for MART-1-(26–35), a dominant melanoma epitope restricted by human leukocyte antigen (HLA)-A*0201, are exceptionally common in the naive T-cell repertoire. Remarkably, the *TRAV12-2* gene is used to encode the T-cell receptor α (TCR α) chain in >87% of these T-cells. Here, the molecular basis for this genetic bias is revealed from the structural and thermodynamic properties of an archetypal *TRAV12-2*-encoded TCR complexed to the clinically relevant heteroclitic peptide, ELAGIGILTV, bound to HLA-A*0201 (A2-ELA). Unusually, the *TRAV12-2* germ line-encoded regions of the TCR dominate the major atomic contacts with the peptide at the TCR/A2-ELA interface. This “innate” pattern of antigen recognition probably explains the unique characteristics and extraordinary frequencies of CD8⁺ T-cell responses to this epitope.

Malignant melanoma is responsible for 75% of all skin cancer-related deaths worldwide, and the global incidence is rising. The MART-1 (1) protein, also known as Melan-A (2), is expressed by virtually all fresh melanoma tumor specimens and elicits natural CD8⁺ T-cell responses (3, 4) that can lead to spontaneous disease regression (reviewed in Ref. 5). Consequently, CD8⁺ T-cell responses directed against the MART-1 protein have been investigated extensively (reviewed in Refs. 2, 6, and 7), and heteroclitic forms of the dominant MART-1-(26–35) peptide epitope (8, 9), which is restricted by human leukocyte antigen (HLA)-A*0201, are currently being used in a number of clinical trials (10–12). In recent developments, adoptive T-cell therapy directed against the MART-1 protein has been used to mediate cancer regression in ~50% of late

stage melanoma patients (13). However, these approaches have not proved to be universally effective, and there remains considerable scope for improvement. In order to design more effective immune-based therapies against the MART-1 protein, it is essential to understand the precise molecular rules that govern the interaction between T-cell receptors (TCRs)⁶ and the HLA-A*0201·MART-1-(26–35) complex. Previous structural studies of human TCR/peptide major histocompatibility complex (pMHC) interactions (14–16) indicate that specific regions of the TCR have different roles during antigen engagement; thus, the germ line-encoded complementarity-determining region 1 and 2 (CDR1 and -2) loops contact mainly the conserved helical region of the MHC surface, and the more variable somatically rearranged CDR3 loops contact mainly the antigenic peptide. Dissecting the nature of these contacts, which have been shown to be highly variable for individual TCR/pMHC interactions (17–19), is an important step toward understanding the principles of antigen recognition and for the development of improved T-cell vaccines (20). However, the current data base of human TCR·pMHC complexes reported in the literature is limited (~16), compared with >100 antibody-antigen structures. This has made it difficult to ascertain whether there are conserved binding modes for TCR/pMHC interactions dictated by a number of specific contacts or whether there are potentially unlimited numbers of TCR docking orientations dependent on the nature of individual recognition events. Furthermore, there are no examples to date of human TCR·pMHC class I structures in which the bound peptide is a decamer; this represents a substantial deficiency in our current knowledge, given the preponderance with which decamer peptides are processed, presented, and recognized. The low number of TCR·pMHC complex structures solved to date reflects technical difficulties inherent in the production of soluble TCR and pMHC molecules that retain stability and challenges related to the crystallization of complexes with relatively low binding affinities ($K_D = 0.1$ – $500 \mu\text{M}$) (21, 22). In general, TCRs specific for tumor-derived epitopes bind in the weaker range of TCR/

* This work was supported in part by the Cardiff University Link Chair Scheme and by Biotechnology and Biological Sciences Research Council (BBSRC) UK Grant BB/H001085/1, which enabled the establishment of protein crystallography at Cardiff University School of Medicine.

The atomic coordinates and structure factors (code 3HG1) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (<http://www.rcsb.org/>).

¹ These authors contributed equally to this work.

² Leverhulme Early Career Fellow.

³ NHMRC Biomedical Fellow.

⁴ Medical Research Council (UK) Senior Clinical Fellow.

⁵ To whom correspondence should be addressed. Tel.: 44-29-206-87055; Fax: 44-29-206-87007; E-mail: sewellak@cardiff.ac.uk.

⁶ The abbreviations used are: TCR, T-cell receptor; MHC, major histocompatibility complex; pMHC, peptide major histocompatibility complex; CDR, complementarity-determining region; HLA, human leukocyte antigen; vdW, van der Waals; A2-ELA, ELAGIGILTV bound to HLA-A*0201; pMHCI, pMHC class I; $\beta 2\text{m}$, $\beta 2$ -microglobulin.

Innate-like Recognition by a Human T-cell Receptor

pMHC affinities (21). This obstacle to the generation of high quality co-complex crystals is underscored by the fact that only one other tumor-specific human TCR-pMHC complex structure has been documented previously (23).

In this study, we expressed a soluble TCR (MEL5) specific for ELAGIGILTV, the common MART-1-(26–35) heteroclitic peptide, complexed to HLA-A*0201 (A2-ELA). Notably, HLA-A*0201 is the most common HLA allele in the human population (24). The CDR1 and CDR2 loops of this TCR are encoded by the *TRAV12-2* and *TRBV30* genes (International Immunogenetics (IMGT) nomenclature). Interestingly, the *TRAV12-2* gene is expressed in the vast majority of CD8⁺ T-cell populations specific for HLA-A*0201·MART-1-(26–35) across multiple individuals (25, 26). To resolve the enigma of the dominant *TRAV12-2* gene and determine the molecular characteristics that govern CD8⁺ T-cell recognition of the HLA-A*0201·MART-1-(26–35) antigen, we performed a biophysical, thermodynamic, and structural analysis of MEL5 TCR binding to A2-ELA. The data provide a molecular basis for biased TCR gene product selection in the CD8⁺ T-cell response to HLA-A*0201·MART-1-(26–35) and indicate that pMHC antigens can be subject to “innate-like” binding modes within adaptive immune responses.

EXPERIMENTAL PROCEDURES

Generation of CD8⁺ T-cell Clones Specific for HLA-A*0201·MART-1-(26–35)—CD8⁺ T-cell clones were generated as described previously (27). Briefly, peripheral blood mononuclear cells, isolated from an HLA-A*0201⁺ healthy donor, were stimulated with 1 nM ELAGIGILTV peptide and cloned via limiting dilution. These cells were then screened for A2-ELA tetramer binding. The MEL5 CD8⁺ T-cell clone isolated from these experiments activated typically in response to HLA-A*0201⁺ target cells pulsed with the ELAGIGILTV peptide, exhibiting specific degranulation (CD107a mobilization) and the production of interferon- γ , interleukin-2, and tumor necrosis factor- α (data not shown). The MEL5 TCR was derived from the MEL5 CD8⁺ T-cell clone. Two independent CD8⁺ T-cell clones grown in the same way, MEL11 and MEL13, were shown to express an identical TCR.

Generation of Expression Plasmids—The MEL5 TCR, HLA-A*0201 α chain and β 2m sequences were generated by PCR mutagenesis (Stratagene) and PCR cloning. All sequences were confirmed by automated DNA sequencing (Lark Technologies). For MEL5, a disulfide-linked construct was used to produce the soluble domains (variable and constant) for both the α and β chains (28, 29). The soluble HLA-A*0201 α chain (α 1, α 2, and α 3 chain domains), tagged with a biotinylation sequence, and β 2m were also cloned and used to make the HLA-A*0201 protein. The TCR, HLA-A*0201 α chain, and β 2m sequences were inserted into separate pGMT7 expression plasmids under the control of the T7 promoter (28).

Protein Expression, Refolding, and Purification—Competent Rosetta DE3 *Escherichia coli* cells were used to produce the MEL5 α and β chains and the HLA-A*0201 α and β 2m chains in the form of inclusion bodies, using 0.5 mM isopropyl 1-thio- β -D-galactopyranoside to induce expression, as described pre-

viously (28). For a 1-liter refold, 30 mg of MEL5 α chain inclusion bodies were incubated at 37 °C for 15 min with 10 mM dithiothreitol and added to cold refold buffer (50 mM Tris, pH 8.1, 2 mM EDTA, 2.5 M urea, 6 mM cysteamine hydrochloride, and 4 mM cystamine). After 15 min, 30 mg of MEL5 β chain, incubated at 37 °C for 15 min with 10 mM dithiothreitol, was added. For a 1-liter A2-ELA refold, 30 mg of α chain was mixed with 30 mg of β 2m and 4 mg of the ELAGIGILTV peptide at 37 °C for 15 min. This was then added to cold refold buffer (50 mM Tris, pH 8, 2 mM EDTA, 400 mM L-arginine, 6 mM cysteamine hydrochloride, and 4 mM cystamine). Refolds were mixed at 4 °C for >1 h. Dialysis was carried out against 10 mM Tris, pH 8.1, until the conductivity of the refolds was under 2 millimhos/cm. The refolds were then filtered in preparation for the purification steps. Refolded proteins were purified initially by ion exchange using a Poros50HQTM column and finally gel-filtered into BIAcore buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.005% (v/v) Surfactant P20) or crystallization buffer (10 mM Tris, pH 8.1, 10 mM NaCl) using a Superdex200HRTM column. Protein quality was analyzed by Coomassie-stained SDS-PAGE.

pMHC Biotinylation—Biotinylated pMHC was prepared as described previously (30).

Surface Plasmon Resonance Analysis—Binding analysis was performed independently using a BIAcore T100TM equipped with a CM5 sensor chip, as reported previously (31). Between 200 and 400 response units of biotinylated pMHC was immobilized to streptavidin, which was chemically linked to the chip surface. The pMHC was injected at a slow flow rate (10 μ l/min) to ensure uniform distribution on the chip surface. Combined with the small amount of pMHC bound to the chip surface, this reduced the likelihood of off-rate-limiting mass transfer effects. MEL5 was purified and concentrated to \sim 100 μ M on the same day of surface plasmon resonance analysis to reduce the likelihood of TCR aggregation affecting the results. For equilibrium and kinetic analysis, 10 serial dilutions were carefully prepared in triplicate for each sample and injected over the relevant sensor chips at 25 °C. MEL5 was injected over the chip surface using kinetic injections at a flow rate of 45 μ l/min. For the thermodynamic experiments, this method was repeated at the following temperatures; 5, 13, 21, 25, 29, and 37 °C. Results were analyzed using BIAevaluation 3.1TM, Microsoft ExcelTM, and Origin 6.1TM. The equilibrium binding constant (K_D) values were calculated using a nonlinear curve fit ($y = (P_1x)/(P_2 + x)$). The thermodynamic parameters were calculated using the Gibbs equation ($y = dH + dCp \times (x - 298) - x \times dS - x \times dCp \times \ln(x/298)$).

Crystallization—The MEL5·A2-ELA complex was crystallized as reported previously (32).

Diffraction Data Collection and Model Refinement—A data set up to 3.0 Å was collected with the rotation method at Synchrotron Radiation Source Station 14.2 (Daresbury, UK) using an Area Detection Systems Corporation Quantum 4 CCD-detector system. The wavelength (λ) was set to 0.979 Å. A total of 160 frames were recorded, each covering 0.5° of rotation. The crystal was maintained at 100 K in an Oxford cryostream. Reflection intensities were estimated with the MOSFLM package (33), and the data were scaled, reduced, and analyzed with

TABLE 1
Data collection and refinement statistics (molecular replacement)

One crystal was used for data collection.

| Parameters | Values |
|---|---------------------------|
| Data set statistics^a | |
| Space group | P4 ₃ |
| Unit cell parameters (Å) | $a = b = 120.9, c = 82.0$ |
| Radiation source | SRS 14.2 |
| Wavelength (Å) | 0.978 |
| Resolution (Å) | 3.0 (3.16–3.0) |
| Reflections observed | 80,204 (11,687) |
| Unique reflections | 23,764 (3,464) |
| Completeness (%) | 99.5 (100.0) |
| Multiplicity | 3.4 (3.4) |
| $I/\sigma(I)$ | 8.0 (1.6) |
| R_{merge} (%) | 15.1 (79.4) |
| Refinement statistics^a | |
| Measured resolution range (Å) | 48.7–3.0 |
| No. of reflections used | 22,525 (1,652) |
| No. of reflections in the R_{free} set | 1,211 (88) |
| R_{cryst} (no cut-off) (%) | 22.5 |
| R_{free} (%) | 30.4 |
| Root mean square deviation from ideal geometry^b | |
| Bond lengths (Å) | 0.02 (0.021) |
| Bond angles (degrees) | 1.2 (1.936) |
| Mean B value (Å ²) | 40.5 |
| Wilson B -factor (Å ²) | 47.6 |
| Overall coordinate error (Å) | 0.4 |

^a Values in parentheses are for the highest resolution shell.

^b Values in parentheses are target values.

SCALA and the CCP4 package (34). The structure was solved with molecular replacement using PHASER (35). Despite close similarity to NY-ESO-1 complexes solved recently (e.g. 2P5E or 2P5W), a solution could be obtained only with a composite search model constructed with CHAINSAW as follows. The HLA-A*0201 α chain (A) was taken from Protein Data Bank entry 2F53, the β 2m chain (B) was taken from Protein Data Bank entry 2BCK, the TCR α chain (D) was taken from Protein Data Bank entry 1A07, and the TCR β chain (E) was taken from Protein Data Bank entry 2F53. The peptide was not included at this stage, since it was only a small fraction of the diffracting material. The model sequence was adjusted with COOT (36), and the model was refined with REFMAC5, version 5.2.0019 (37). The model was split into eight domains for TLS refinement (A2 α 1 α 2, A2 α 3, β 2m, ELA peptide, MEL5 α constant, MEL5 α variable, MEL5 β constant and MEL5 β variable). After convergence, one round of restrained thermal parameters was completed, in order to obtain the full B values for atoms. Graphical representations were prepared with PyMOL (38). Data collection and reduction statistics and refinement statistics are shown in Table 1.

RESULTS

Structure Determination and Analysis of MEL5 in Complex with A2-ELA—To investigate the structural basis for dominant TRAV12-2 gene usage in CD8⁺ T-cell populations specific for HLA-A*0201·MART-1-(26–35), we solved the atomic structure of MEL5 in complex with A2-ELA (Table 1; Fig. 1A). Molecular replacement was successful only in space group P4₃, consistent with the presence of one molecule of the complex per asymmetric unit, and the resolution was sufficiently high to show that the interface between the two molecules was well ordered and contained well defined electron density. The final model showed ~96% of residues in the preferred and allowed




FIGURE 1. A, the co-crystal structure of MEL5 (α chain shown as a yellow schematic diagram, β chain shown as a salmon schematic diagram) bound to the HLA-A*0201 (shown as green and blue schematic diagrams) molecule complexed with the ELA peptide (shown as blue sticks). B, expanded view of the interface between the MEL5 variable domain bound to the A2-ELA surface (colors as in A). The overall conformation of the ELA peptide (N to C terminus, left to right), including the central peptide bulge, is displayed. C, view from above of the MEL5 CDR loops bound to the A2-ELA surface (colors as in A; MEL5 CDR loops shown as spheres). The MEL5 TCR binds toward the N terminus of the peptide, making contacts with the peptide via its CDR1 and CDR3 loops and contacts with the MHC surface via its CDR1 and CDR2 loops.

regions of the Ramachandran plot and geometry consistent with the data resolution. The crystallographic R/R_{free} factors were 22.5 and 30.4%. There was enough ordered density around the protein model to allow the identification of two glycerol molecules, 2 sulfate ions, and 44 solvent (water) molecules. The C terminus of the TCR α chain was disordered beyond residue 195, with no apparent electron density beyond that point.

The MEL5 docking angle with A2-ELA was 35° (calculated as in Ref. 14), with the TCR α chain contacting the α 2 domain and the TCR β chain contacting the α 1 domain of A2-ELA (Fig. 1, A–C). The docking angle in this complex lies within the range observed for other human TCR·pMHC complexes, with the A6 TCR·A2-Tax complex representing one extreme (32°) (28) and the 1G4 TCR·A2-NY-ESO (23) complex representing the other extreme (69°). The TCR was located toward the N terminus of the MHC peptide binding groove, as observed in the A6 TCR·A2-Tax and B7 TCR·A2-Tax complexes (39, 40), and centered over the solvent-exposed bulge of the ELA peptide (Fig. 1, B and C).

The total buried surface area of the interaction was ~1226 Å², the lowest for any human TCR/pMHC interaction reported to date. This supports the observation that MEL5 makes significantly fewer contacts with the pMHC surface compared with other TCR·pMHC complexes, which indicates that T-cell recognition of antigen can occur with a lower number of specific contacts than previously thought. Although the ELA peptide is a decamer, the contribution of the peptide (29% of the interface

TABLE 2
MEL5/A2-ELA contacts

Contacts were calculated using a 4Å cut-off.

| CDR loop | TCR residue | Peptide residue | MHC residue | Bond type | Bond distance | |
|------------------------------|--------------------------------|--------------------------------|--------------------------------|----------------------------|---------------|-----|
| CDR1 α | Arg ²⁸ Ne | | Glu ¹⁶⁶ Oe2 | Electrostatic ^a | 3.4 | |
| | Arg ²⁸ NH2 | | Glu ¹⁶⁶ Oe2 | Electrostatic | 3.1 | |
| | Arg ²⁸ O | | Trp ¹⁶⁷ Ne1 | Electrostatic | 3.7 | |
| | Arg ²⁸ NH2 | | Glu ¹⁶⁶ Oe1 | Electrostatic | 3.5 | |
| | Gln ³¹ Ne2 | Glu ¹ Oe2 | | Electrostatic | 3.4 | |
| | Gln ³¹ Ne2 | Leu ² O | | Electrostatic | 3.4 | |
| | Gln ³¹ C δ | Gly ⁴ N | | vdW ^b | 3.3 | |
| | Gln ³¹ Oe1 | Gly ⁴ C α | | vdW | 3.0 | |
| | Gln ³¹ Oe1 | Gly ⁴ N | | Electrostatic | 2.5 | |
| | Gln ³¹ Oe1 | Ile ⁵ N | | Electrostatic | 3.5 | |
| | CDR2 α | Tyr ⁵¹ OH | | His ¹⁵¹ O | Electrostatic | 3.9 |
| | CDR3 α | Asn ⁹² N δ 2 | Gly ⁴ O | | Electrostatic | 3.2 |
| | CDR2 β | Gln ⁵⁵ Oe1 | | Arg ⁷⁵ NH1 | Electrostatic | 3.3 |
| Glu ⁵⁹ Oe1 | | | Arg ⁶⁵ NH1 | Electrostatic | 2.8 | |
| Glu ⁵⁹ Oe2 | | | Arg ⁶⁵ NH1 | Electrostatic | 3.5 | |
| Glu ⁵⁹ C δ | | | Arg ⁶⁵ NH1 | vdW | 3.4 | |
| CDR3 β | Gly ⁹⁷ C α | | Thr ⁷³ C γ 2 | vdW | 2.9 | |
| | Gly ⁹⁹ C α | | Gln ¹⁵⁵ Oe1 | vdW | 3.4 | |
| | Thr ¹⁰⁰ N | | Gln ¹⁵⁵ Oe1 | Electrostatic | 2.9 | |
| | Thr ⁹⁶ O γ 1 | Thr ⁹ O γ 1 | | Electrostatic | 3.8 | |
| | Leu ⁹⁸ C γ 2 | Ala ³ O | | vdW | 3.3 | |
| | Leu ⁹⁸ O | Gly ⁴ O | | vdW | 3.2 | |
| | Leu ⁹⁸ O | Ile ⁵ C α | | vdW | 3.2 | |
| | Leu ⁹⁸ O | Gly ⁶ N | | Electrostatic | 3.9 | |
| | Leu ⁹⁸ O | Ile ⁷ N | | Electrostatic | 3.8 | |
| | Leu ⁹⁸ N | Ile ⁷ O | | Electrostatic | 3.2 | |
| | Gly ⁹⁹ N | Ile ⁷ O | | Electrostatic | 3.4 | |
| | Gly ⁹⁹ O | Ile ⁵ C α | | vdW | 3.3 | |
| | Gly ⁹⁹ O | Ile ⁵ C γ 2 | | vdW | 3.3 | |

^a Electrostatic, polar contacts.

^b vdW, non-polar van der Waals contacts.

area) to TCR binding was within the normal range observed for other TCR·pMHC complexes (18–34%) that typically contain nonamers in the peptide binding groove. The contribution of the TCR α and TCR β chains has been shown to vary markedly for different human TCR·pMHC complexes, the largest difference being observed for the JM22 TCR·A2-Flu complex (41) (α chain, 33%; β chain, 67%). For the MEL5·A2-ELA complex, the interaction was split relatively evenly (α chain, 50.4%; β chain, 49.6%). The surface complementarity across the interface as a whole was 0.63, with a slightly lower score of 0.58 between the MHC and the TCR alone. However, the score increased to 0.76 when the TCR and the peptide interface were considered, indicating a much closer and more directed match.

MEL5/A2 Contacts—MEL5 forms 12 contacts, comprising nine electrostatic interactions and three van der Waals (vdW) close interactions, with the conserved MHC α helices of HLA-A*0201 that constitute the sides of the peptide binding groove (Table 2). These contacts are dominated by the CDR1 α loop, which is located over the N terminus of the ELA peptide and makes a significant contribution to the TCR/MHC α 2 helix interface, forming a dense network of four electrostatic interactions between the TCR α chain residue Arg²⁸ and the MHC α 2 residues Glu¹⁶⁶ and Trp¹⁶⁷. Notably, the CDR1 β loop plays no part in contacting the A2-ELA antigen (Table 2). Further contacts were evident between the MHC α 1 helix and the TCR CDR3 α , CDR2 β , and CDR3 β loops, as detailed in Table 2. A number of conserved, or “gatekeeper,” interactions that are present in the majority of TCR·pMHC complex structures solved to date (14), were also present between MEL5 and the MHC surface. These include electrostatic interactions between the TCR residue Glu⁵⁹ and the MHC residue Arg⁶⁵




FIGURE 2. A, the interactions between the CDR loops of MEL5 α chain (shown as yellow sticks) and the ELA peptide (shown as blue sticks). Electrostatic interactions are depicted as black dotted lines, and vdW interactions are shown as red dotted lines. B, the interactions between the CDR loops of MEL5 β chain (shown as salmon sticks) and the ELA peptide (shown as blue sticks). Electrostatic interactions are depicted as black dotted lines, and vdW interactions are shown as red dotted lines.

and between the TCR residues Gly⁹⁹ and Thr¹⁰⁰ and the MHC residue Gln¹⁵⁵. Interestingly, MEL5 does not contact MHC α 1 domain residue Arg⁶⁹ or Gln⁷², which represent the other “gatekeeper” TCR/MHC contacts (14).

A2-ELA Conformation in Uncomplexed and TCR-complexed Forms—The crystal structure of uncomplexed A2-ELA has been solved (42). Although the ELA peptide is a decamer, it adopts a similar conformation to nonamer peptides with a central bulge between residues 4 and 6 (Fig. 2A). In the case of the ELA peptide, the extra residue is accommodated, not through a more prominent central bulge but by an extension of the peptide C α chain toward the α 2 domain of the HLA-A*0201 binding groove. Superposition of the uncomplexed A2-ELA and the MEL5-complexed A2-ELA structures shows that the peptide termini are located at virtually identical positions. This peptide conformation results in the availability of a number of residues for specific TCR contacts; these include Glu^{P1}, Leu^{P2}, Ala^{P3}, Gly^{P4}, Ile^{P5}, Gly^{P6}, Ile^{P7}, Leu^{P8}, and Thr^{P9} (Fig. 2). Compared with the uncomplexed A2-ELA structure, the conformation of the ELA peptide upon docking with the TCR is very similar, with a root mean square deviation value of 0.369 between the peptides in uncomplexed and TCR-complexed forms. There




FIGURE 3. *A*, the position of the CDR1 α and CDR2 α loops, encoded by the *TRAV12-2* gene, of MEL5 (shown as yellow spheres) in the HLA-A*0201 (shown as a green schematic diagram) ELAGIGILTV peptide (shown as blue sticks) complex. *B*, the positions of the CDR1 α and CDR2 α loops, encoded by the *TRAV12-2* gene, of the A6 TCR (shown as orange spheres) in the HLA-A*0201 (shown as a blue schematic diagram) LLFGYPVYV peptide (shown as red sticks) complex. *C*, the conserved interactions (shown as dotted lines) between the CDR1 α and CDR2 α loops, encoded by the *TRAV12-2* gene, of MEL5 (shown as yellow sticks) and the HLA-A*0201 (shown as green sticks) ELAGIGILTV peptide (shown as blue sticks) complex. *D*, the conserved interactions (shown as dotted lines) between the CDR1 α and CDR2 α loops, encoded by the *TRAV12-2* gene, of the A6 TCR (shown as orange sticks) and the HLA-A*0201 (shown as blue sticks) LLFGYPVYV peptide (shown as red sticks) complex.

are some conformation differences in the side chains of Leu^{P8}, and Thr^{P9}, which adopt visually different conformations in the uncomplexed A2-ELA structure; however, these differences are within experimental error and may not represent changes in peptide conformation due to stabilization of the peptide upon TCR docking.

The Dominant Role of the *TRAV12-2*-encoded CDR1 Loop during Peptide Binding—MEL5 contacts eight of the A2-ELA peptide residues (Table 2 and Fig. 2*B*), compared with only three for the immunodominant LC13 TCR·B8-EBNA (43) and the four for JM22 TCR·A2-Flu (41) complexes. Unusually, the CDR3 α loop has a minimal role in contacting the ELA peptide, making only one electrostatic interaction between TCR residue Asn⁹² and the ELA peptide at Gly^{P4}. A substantial number of contacts at the interface are formed between Gln³¹ in the CDR1 α loop, encoded by the *TRAV12-2* gene, and the antigenic peptide (Table 2). The Gln³¹ residue makes a dense network of contacts to Glu^{P1}, Leu^{P2}, Gly^{P4}, and Ile^{P5} and is therefore likely to have a chief role in peptide recognition (Table 2 and Fig. 2*B*). In this unusual TCR binding mode, the CDR1 α loop acts in a manner comparable with that of a classical CDR3 loop with respect to peptide contacts. The dominance of the CDR1 α loop in terms of contacting both the surface of HLA-A*0201 and the bound ELA peptide could explain the prevalent expression of the *TRAV12-2* gene in CD8⁺ T-cell responses specific for

MART-1-(26–35) (26). Furthermore, the *TRAV12-2* gene, which encodes the CDR1 α and CDR2 α loops of MEL5, is also expressed by the A6 TCR, which is specific for the Tax-(11–19) peptide (LLFGYPVYV) bound to HLA-A*0201 (A2-Tax) (28). The CDR1 α and CDR2 α loops of the A6 TCR utilize an antigen binding mode virtually identical to that seen in the MEL5·A2-ELA complex, with both TCRs making contacts between CDR1 α loop residue Arg²⁸ and MHC α 2 residue Trp¹⁶⁷ and between CDR1 α loop residue Gln³¹ and peptide positions 1 and 4 (Glu^{P1} and Gly^{P4} for A2-ELA; Leu^{P1} and Gly^{P4} for A2-Tax) (Fig. 3). In all other published TCR·pMHC complexes, the CDR1 α and CDR2 α loops, which are not encoded by the *TRAV12-2* gene, form unique contacts with their respective pMHC complexes compared with the MEL5·A2-ELA complex; this observation lends credence to the idea that TCRs expressing the *TRAV12-2* gene could have a selective advantage when binding to cognate antigen restricted by HLA-A*0201 due to germ line-encoded, or “innate,” recognition of

residues on the MHC surface and in the bound peptide. Consequently, although the TCR α and TCR β chains contribute relatively equally in both the A6 TCR and MEL5 complexes, the conservation in the position of the TCR α chain in both complexes indicates that the A6 TCR and MEL5 bind to their cognate pMHCs in an “ α -centric” manner (*i.e.* the binding position of these TCRs is governed by the α chain).

The Role of the TCR β Chain during Peptide Binding—The TCR β chain utilizes a classical peptide binding mode, interacting with the ELA peptide solely through contacts made by the CDR3 β loop. In total, the CDR3 β loop makes five hydrogen bonds and five vdW interactions between Thr⁹⁶, Leu⁹⁸, and Gly⁹⁹ of the TCR and Ala^{P3}, Gly^{P4}, Ile^{P5}, Gly^{P6}, Ile^{P7}, and Thr^{P9} of the peptide. However, all of the hydrogen bonds, which constitute the majority of the binding energy, are located between the CDR3 β loop and the C terminus of the peptide (Gly^{P6}, Ile^{P7}, and Thr^{P9}). Interestingly, the position of the CDR3 β loop enables a dense network of interactions, including three hydrogen bonds, between TCR residues Leu⁹⁸ and Gly⁹⁹ and peptide residue Ile^{P7}. These contacts are noteworthy, because the side chain of Ile^{P7} acts like an anchor, pointing down toward the MHC surface, thereby making it an unusual candidate for TCR binding. Thus, the contacts between the CDR3 β loop and the ELA peptide contribute significantly to the binding stability of the MEL5·A2-ELA complex.

Innate-like Recognition by a Human T-cell Receptor




FIGURE 4. Binding affinity and thermodynamics of the MEL5/A2-ELA interaction. These data were produced by surface plasmon resonance experiments using a BIAcore T100™ machine, which were then analyzed using equilibrium analysis and thermodynamic analysis using the Gibbs equation. The raw data and the fits are shown in A–G. These data illustrate the unusual thermodynamic properties of the MEL5/A2-ELA interaction (G).

TABLE 3
Thermodynamic analysis of the MEL5/A2-ELA interaction

| Parameters | Values |
|----------------------------|--------|
| Temperature (°C) | 25 |
| K_D (μM) | 18 |
| ΔG^0 (kcal/mol) | –6.5 |
| ΔH^0 (kcal/mol) | 2 |
| $T\Delta S^0$ (kcal/mol) | 8.3 |
| ΔCp^0 (kcal/mol·K) | –0.14 |

Binding Affinity and Thermodynamics of the MEL5·A2-ELA Complex—We have previously shown that MEL5 binds to A2-ELA with a comparatively weak affinity and extremely fast kinetics compared with other TCR/pMHC interactions ($K_D = 18 \mu\text{M}$; kinetics too fast to measure) (21). To investigate the thermodynamic properties of this interaction, we measured the

binding of MEL5 to A2-ELA at 5, 13, 21, 25, 29, and 37 °C using a BIAcore T100™ surface plasmon resonance detection system (Fig. 4 and Table 3). The affinity of the MEL5/A2-ELA interaction increased from $K_D = 26.9 \mu\text{M}$ at 5 °C to $K_D = 17.3 \mu\text{M}$ at 37 °C (Fig. 4, A–F). The affinity data were plotted as binding ΔG^0 versus temperature using nonlinear regression to fit the three-parameter equation to the curve in order to calculate ΔH^0 , $T\Delta S^0$, and ΔCp^0 (Fig. 4G). At 25 °C, the MEL5/A2-ELA interaction was characterized by a ΔG^0 of –6.5 kcal/mol, which is within the normal range for TCR/pMHC interactions (Table 3). The MEL5/A2-ELA interaction is strongly entropically driven, with a favorable $T\Delta S^0$ of 8.3 kcal/mol. This favorable entropy is likely to be derived mainly from the expulsion of ordered water molecules upon complex formation, allowing the TCR to contact the pMHC surface directly and form the electrostatic and vdW interactions evident in the co-complex structure. Interestingly, this is the first published instance of a TCR/pMHC interaction that is enthalpically unfavorable, with a ΔH^0 of 2 kcal/mol. This indicates that there is a net decrease in the number of favorable non-covalent bonds (hydrogen bonds and vdW contacts) during complex formation and reinforces the importance of the favorable entropic contribution to the binding of MEL5 to A2-ELA. Furthermore, this observation could explain the extremely fast kinetics of the MEL5/A2-ELA interaction (*i.e.* the net loss of bond formation could lead to the observed low stability, and hence the fast off-rate, of the complex). During complex formation, there is normally a net increase in the total buried surface area, which results in a negative ΔCp^0 value. In the case of the MEL5/A2-ELA interaction, however, a relatively small ΔCp^0 value (–0.14 kcal/mol·K) was observed compared with other TCR·pMHC complexes. This supports the observation that the total buried surface area of 1226 Å² for the MEL5·A2-ELA complex is the smallest reported to date for any TCR·pMHC complex.

DISCUSSION

Here, we report the structure of an archetypal *TRAV12-2*-encoded TCR (MEL5), derived from a CD8⁺ T-cell clone specific for MART-1-(26–35) in complex with A2-ELA. A2-ELA is currently the most studied heteroclitic peptide in the literature and is central to a number of clinical trials (10–12). Although the A2-ELA peptide (ELAGIGILTV) is a heteroclitic version of the MART-1-(26–35) peptide (EAAGIGILTV), structural evidence suggests that the substitution of Ala to Leu at the peptide anchor position 2 does not substantially alter the peptide conformation (42, 44). Thus, an understanding of the molecular basis for T-cell recognition of this antigen should inform the rational improvement of current melanoma therapies.

Previous investigations have shown that CD8⁺ T-cells engage the HLA-A*0201·MART-1-(26–35) antigen with predictable TCR gene usage patterns (26, 45). Thus, these particular TCRs show class II bias (shared *TRBV* and/or *TRAV* usage among individuals bearing the same MHCI allele) and class III bias (identical TCRs among individuals bearing the same MHCI allele) (46); interestingly, they can also be detected both in tumor-infiltrated lymph nodes and in the blood of healthy individuals and newborns (26, 45). T-cells specific for

the HLA-A*0201 MART-1-(26–35) antigen display striking bias in *TRAV* gene usage. A recent study revealed 47 of 53 CD8⁺ T-cell clones (87%) raised on the HLA-A*0201 MART-1-(26–35) target expressed a TCR of the *TRAV12-2* family (26). This bias was observed across numerous individuals. Since the *TRAV12-2* gene is only expressed on the surface of ~3% of circulating lymphocytes (47), the very high prevalence of *TRAV12-2* usage in these melanoma-specific CD8⁺ T-cell responses indicates that this particular gene is advantageous during antigen-driven selection. The *TRAV12-2*-encoded regions of the MEL5 TCR play a dominant role at both the peptide and MHC interface. The CDR1 α residue Arg²⁸ helps to fix the TCR to the MHC α 2 helix via four electrostatic interactions, whereas the CDR1 α residue Gln³¹ appears integral to peptide recognition through two vdW bonds and four electrostatic interactions to Glu^{P1}, Leu^{P2}, Gly^{P4}, and Ile^{P5}. In general, the CDR1 α loop plays a role comparable with that of the CDR3 loop in other TCR·pMHC structures, given its central position above the N terminus of the peptide and the extensive binding networks between the CDR1 α loop and bound peptide. It is striking to note that residues encoded by the *TRAV12-2* gene make 9 of 19 of the electrostatic interactions with A2-ELA, more than any of the other TCR regions in this structure. Furthermore, when the bonding networks are taken into account, it becomes clear why the *TRAV12-2* subfamily is heavily selected *in vivo*. For instance, only 3 of 47 *TRAV* genes encode Arg at position 28, and only 3 of 47 *TRAV* genes encode Gln at position 31; only the *TRAV12-2* gene encodes both. In fact, even the highly homologous sister genes of *TRAV12-2*, specifically *TRAV12-1* and *TRAV12-3*, probably could not be substituted, given that they encode a polar, uncharged Ser at position 28. This single substitution would probably result in the loss of four electrostatic interactions at the pMHC interface. In support of this idea, no TCRs specific for the HLA-A*0201·MART-1-(26–35) complex have so far been found that use either the *TRAV12-1* or the *TRAV12-3* genes (26). Thus, the dominant selection of this “quasi-innate,” self-reactive TCR probably represents an advantageous role during host responses against the HLA-A*0201·MART-1-(26–35) antigen that cannot be fulfilled by TCRs of alternate specificities.

Further inspection of the MEL5·A2-ELA complex reveals additional features that could contribute to the dominant expression of the *TRAV12-2*-encoded CDR1 α loop in CD8⁺ T-cell responses specific for HLA-A*0201·MART-1-(26–35). Strikingly, MEL5 contacts primarily the main chain of the ELA peptide; indeed, only 3 of 17 peptide contacts are side chain interactions. This is disparate from the more equal distribution of side chain *versus* main chain peptide interactions observed in most other TCR·pMHC structures and implies that MEL5 may be less sensitive to peptide sequence relative to peptide conformation. Moreover, the somatically rearranged CDR3 β loop principally utilizes main chain atoms to contact the peptide, whereas the germ line-encoded CDR1 α loop uses predominantly side chain atoms to contact the peptide. This interesting dichotomy of binding strategies between the CDR3 β and CDR1 α loops in the MEL5·A2-ELA complex may have implications for antigen specificity; thus, changes in the sequence of the CDR3 β loop may be tolerated when binding to A2-ELA as

long as the overall conformation of the loop is maintained, whereas changes in the sequence of the CDR1 α loop may disrupt T-cell recognition of A2-ELA due to loss of side chain-specific interactions.

Interestingly, the *TRAV12-2* gene is also used by the A6 TCR, which is specific for the A2-Tax complex; this is the first structural example in which an identical gene is shared between TCRs specific for a tumor antigen (MEL5·A2-ELA) and a viral antigen (A6 TCR·A2-Tax). In both of these TCR·pMHC complexes, the *TRAV12-2* gene-encoded CDR1 α loops are suspended over the N terminus of their respective cognate pMHC molecules. This feature enables the CDR1 α loops of each TCR to form far more contacts with the antigenic peptide compared with the corresponding CDR3 α loops. In both complexes, the CDR β domains conform to the classical model of TCR·pMHC binding, with the CDR2 β loop contributing mainly to MHC contacts and the CDR3 β loop contributing mainly to peptide interactions. Furthermore, despite the fact that MEL5 and the A6 TCR are encoded by unique TCR β chain genes (*TRBV30* and *TRBV6-5*, respectively), the TCRs align in virtually identical positions and orientations over the respective cognate pMHC molecules in both the MEL5·A2-ELA and the A6 TCR·A2-Tax complexes, thereby indicating that the TCR α chain encoded by the *TRAV12-2* gene has a dominant role during TCR·pMHC docking compared with the TCR β chain. This observation lends support to the idea that MEL5 and the A6 TCR are “ α -centric” (*i.e.* their binding orientation is governed by common contacts between the TCR α chain and the MHC surface) (18). Moreover, despite the unique sequences of the peptides in the A2-ELA (ELAGIGILTV) and A2-Tax (LLFGYPVYV) complexes, the binding mode implemented by the CDR1 α loop encoded by the germ line *TRAV12-2* gene in both the MEL5·A2-ELA complex and the A6 TCR·A2-Tax complex is virtually identical; thus, contacts between the CDR1 α loop residue Arg²⁸ and the MHC α 2 residue Trp¹⁶⁷ and, most notably, between the CDR1 α loop residue Gln³¹ and peptide positions 1 and 4 (Glu^{P1} and Gly^{P4} for A2-ELA; Leu^{P1} and Gly^{P4} for A2-Tax) are evident in both complex structures (Fig. 3, C and D). Thus, the specificity of MEL5 for the HLA-A*0201·MART-1-(26–35) antigen is achieved not only through the highly variable somatically rearranged CDR3 loops, as observed for other TCR·pMHC complexes, but also through the germ line-derived CDR1 α loop, which contributes significantly to peptide binding. Although considerable contacts between the TCR CDR1 loops and the antigenic peptide have been observed in some other TCR·pMHC complexes (48), this is the first example of specific antigen recognition via identical germ line-encoded receptor loops shared by both anti-viral (A6 TCR·A2-Tax) and anti-self (MEL5·A2-ELA) T-cells.

In summary, this first structure of a human TCR in complex with a decamer peptide bound to MHCII considerably extends our knowledge of TCR/pMHC interactions. First, the MEL5/A2-ELA interaction is the only enthalpically unfavorable TCR interaction ever described (49). Second, the MEL5·A2-ELA complex has the lowest buried surface area (1,226 Å²) of any published TCR·pMHC complex, an observation that is supported by the relatively small ΔC_p^0 value (−0.14 kcal/mol·K). Third, this structure shows that the specificity of MEL5 for

A2-ELA is achieved in large part through interactions with the CDR1 α loop, which contributes significantly to peptide binding and whose function is akin to that of classical CDR3 loops during pMHC binding. The dominance of the germ line-encoded regions in this α -centric TCR during pMHC binding indicates an important role for the *TRAV12-2* gene product in antigen recognition. Thus, TCRs that use the *TRAV12-2* gene may enable CD8⁺ T-cells to recognize and respond to the HLA-A*0201·MART-1-(26–35) antigen through a “quasi-innate” recognition system. These observations probably explain the biased TCR usage that has been observed in CD8⁺ T-cell populations specific for HLA-A*0201·MART-1-(26–35) and further reported in a variety of other human diseases (reviewed in Refs. 46 and 50).

Acknowledgments—We thank the staff at the Synchrotron Radiation Source for use of facilities, the UK Research Councils for supplying beamtime, and Professor Eleanor Dodson for assistance with PHASER for structure solution with molecular replacement.

REFERENCES

- Kawakami, Y., Elyah, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. (1994) *J. Exp. Med.* **180**, 347–352
- Romero, P., Valmori, D., Pittet, M. J., Zippelius, A., Rimoldi, D., Lévy, F., Dutoit, V., Ayyoub, M., Rubio-Godoy, V., Michielin, O., Guillaume, P., Batard, P., Luescher, I. F., Lejeune, F., Liénard, D., Rufer, N., Dietrich, P. Y., Speiser, D. E., and Cerottini, J. C. (2002) *Immunol. Rev.* **188**, 81–96
- Voelter, V., Rufer, N., Reynard, S., Greub, G., Brookes, R., Guillaume, P., Grosjean, F., Fagerberg, T., Michelin, O., Rowland-Jones, S., Pinilla, C., Leyvraz, S., Romero, P., and Appay, V. (2008) *Int. Immunol.* **20**, 1087–1096
- Pittet, M. J., Valmori, D., Dunbar, P. R., Speiser, D. E., Liénard, D., Lejeune, F., Fleischhauer, K., Cerundolo, V., Cerottini, J. C., and Romero, P. (1999) *J. Exp. Med.* **190**, 705–715
- Chodorowski, Z., Anand, J. S., Więniowski, M., Madaliński, M., Wierzbza, K., and Więniowski, J. (2007) *Przegl. Lek.* **64**, 380–382
- Pittet, M. J., Zippelius, A., Valmori, D., Speiser, D. E., Cerottini, J. C., and Romero, P. (2002) *Trends Immunol.* **23**, 325–328
- Kawakami, Y., and Rosenberg, S. A. (1997) *Int. Rev. Immunol.* **14**, 173–192
- Speiser, D. E., Liénard, D., Pittet, M. J., Batard, P., Rimoldi, D., Guillaume, P., Cerottini, J. C., and Romero, P. (2002) *Eur. J. Immunol.* **32**, 731–741
- Valmori, D., Fonteneau, J. F., Lizana, C. M., Gervois, N., Liénard, D., Rimoldi, D., Jongeneel, V., Jotereau, F., Cerottini, J. C., and Romero, P. (1998) *J. Immunol.* **160**, 1750–1758
- Bins, A., Mallo, H., Sein, J., van den Bogaard, C., Nooijen, W., Vyth-Dreese, F., Nuijen, B., de Gast, G. C., and Haanen, J. B. (2007) *J. Immunother.* **30**, 234–239
- Chen, Q., Jackson, H., Shackleton, M., Parente, P., Hopkins, W., Sturrock, S., MacGregor, D., Maraskovsky, E., Tai, T. Y., Dimopoulos, N., Masterman, K. A., Luke, T., Davis, I. D., Chen, W., and Cebon, J. (2005) *Cancer Immun.* **5**, 5
- Meidenbauer, N., Marienhagen, J., Laumer, M., Vogl, S., Heymann, J., Andreesen, R., and Mackensen, A. (2003) *J. Immunol.* **170**, 2161–2169
- Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., Zheng, Z., Nahvi, A., de Vries, C. R., Rogers-Freezer, L. J., Mavroukakis, S. A., and Rosenberg, S. A. (2006) *Science* **314**, 126–129
- Rudolph, M. G., Stanfield, R. L., and Wilson, I. A. (2006) *Annu. Rev. Immunol.* **24**, 419–466
- Tynan, F. E., Reid, H. H., Kjer-Nielsen, L., Miles, J. J., Wilce, M. C., Kostenko, L., Borg, N. A., Williamson, N. A., Beddoe, T., Purcell, A. W., Burrows, S. R., McCluskey, J., and Rossjohn, J. (2007) *Nat. Immunol.* **8**, 268–276
- Armstrong, K. M., Piepenbrink, K. H., and Baker, B. M. (2008) *Biochem. J.* **415**, 183–196
- Borg, N. A., Ely, L. K., Beddoe, T., Macdonald, W. A., Reid, H. H., Clements, C. S., Purcell, A. W., Kjer-Nielsen, L., Miles, J. J., Burrows, S. R., McCluskey, J., and Rossjohn, J. (2005) *Nat. Immunol.* **6**, 171–180
- Feng, D., Bond, C. J., Ely, L. K., Maynard, J., and Garcia, K. C. (2007) *Nat. Immunol.* **8**, 975–983
- Tynan, F. E., Borg, N. A., Miles, J. J., Beddoe, T., El-Hassen, D., Silins, S. L., van Zuylen, W. J., Purcell, A. W., Kjer-Nielsen, L., McCluskey, J., Burrows, S. R., and Rossjohn, J. (2005) *J. Biol. Chem.* **280**, 23900–23909
- Borbulevych, O. Y., Baxter, T. K., Yu, Z., Restifo, N. P., and Baker, B. M. (2005) *J. Immunol.* **174**, 4812–4820
- Cole, D. K., Pumphrey, N. J., Boulter, J. M., Sami, M., Bell, J. I., Gostick, E., Price, D. A., Gao, G. F., Sewell, A. K., and Jakobsen, B. K. (2007) *J. Immunol.* **178**, 5727–5734
- Varela-Rohena, A., Molloy P. E., Dunn, S. M., Li, Y., Suhoski, M. M., Carroll, R. G., Milicic, A., Mahon, T., Sutton, D. H., Laugel, B. E., Moysey, R., Cameron, B. J., Vuidepot, A., Purbhoo, M. E., Cole, D. K., Phillips, R. E., June, C. H., Jakobsen, B. K., Sewell, A. K., and Riley, J. L. (2008) *Nat. Med.* **14**, 1390–1395
- Chen, J. L., Stewart-Jones, G., Bossi, G., Lissin, N. M., Wooldridge, L., Choi, E. M., Held, G., Dunbar, P. R., Esnouf, R. M., Sami, M., Boulter, J. M., Rizkallah, P., Renner, C., Sewell, A., van der Merwe, P. A., Jakobsen, B. K., Griffiths, G., Jones, E. Y., and Cerundolo, V. (2005) *J. Exp. Med.* **201**, 1243–1255
- Krausa, P., Brywka, M., 3rd, Savage, D., Hui, K. M., Bunce, M., Ngai, J. L., Teo, D. L., Ong, Y. W., Barouch, D., and Allsop, C. E. (1995) *Tissue Antigens* **45**, 223–231
- Trautmann, L., Labarrière, N., Jotereau, F., Karanikas, V., Gervois, N., Connerotte, T., Coulie, P., and Bonneville, M. (2002) *Eur. J. Immunol.* **32**, 3181–3190
- Dietrich, P. Y., Le Gal, F. A., Dutoit, V., Pittet, M. J., Trautman, L., Zippelius, A., Cagnet, I., Widmer, V., Walker, P. R., Michielin, O., Guillaume, P., Connerotte, T., Jotereau, F., Coulie, P. G., Romero, P., Cerottini, J. C., Bonneville, M., and Valmori, D. (2003) *J. Immunol.* **170**, 5103–5109
- Laugel, B., van den Berg, H. A., Gostick, E., Cole, D. K., Wooldridge, L., Boulter, J. M., Milicic, A., Price, D. A., and Sewell, A. K. (2007) *J. Biol. Chem.* **282**, 23799–23810
- Garboczi, D. N., Ghosh, P., Utz, U., Fan, Q. R., Biddison, W. E., and Wiley, D. C. (1996) *Nature* **384**, 134–141
- Boulter, J. M., Glick, M., Todorov, P. T., Baston, E., Sami, M., Rizkallah, P., and Jakobsen, B. K. (2003) *Protein Eng.* **16**, 707–711
- Wyer, J. R., Willcox, B. E., Gao, G. F., Gerth, U. C., Davis, S. J., Bell, J. I., van der Merwe, P. A., and Jakobsen, B. K. (1999) *Immunity* **10**, 219–225
- Cole, D. K., Dunn, S. M., Sami, M., Boulter, J. M., Jakobsen, B. K., and Sewell, A. K. (2008) *Mol. Immunol.* **45**, 2700–2709
- Yuan, F., Georgiou, T., Hillon, T., Gostick, E., Price, D. A., Sewell, A. K., Moysey, R., Gavaret, J., Vuidepot, A., Sami, M., Bell, J. I., Gao, G. F., Rizkallah, P. J., and Jakobsen, B. K. (2007) *Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun.* **63**, 758–760
- Leslie, A. G. W. (1992) *Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography*, Vol. 26, Daresbury Laboratory, Warrington, UK
- Collaborative Computational Project 4 (1994) *Acta Crystallogr. D Biol. Crystallogr.* **50**, 760–763
- McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C., and Read, R. J. (2005) *Acta Crystallogr. D Biol. Crystallogr.* **61**, 458–464
- Emsley, P., and Cowtan, K. (2004) *Acta Crystallogr. D Biol. Crystallogr.* **60**, 2126–2132
- Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) *Acta Crystallogr. D Biol. Crystallogr.* **53**, 240–255
- DeLano, W. L. (2002) *The PyMOL Molecular Graphics System*, DeLano Scientific LLC, Palo Alto, CA
- Ding, Y. H., Smith, K. J., Garboczi, D. N., Utz, U., Biddison, W. E., and Wiley, D. C. (1998) *Immunity* **8**, 403–411
- Ding, Y. H., Baker, B. M., Garboczi, D. N., Biddison, W. E., and Wiley, D. C. (1999) *Immunity* **11**, 45–56
- Stewart-Jones, G. B., McMichael, A. J., Bell, J. I., Stuart, D. I., and Jones, E. Y. (2003) *Nat. Immunol.* **4**, 657–663
- Sliz, P., Michielin, O., Cerottini, J. C., Luescher, I., Romero, P., Karplus, M., and Wiley, D. C. (2001) *J. Immunol.* **167**, 3276–3284

43. Kjer-Nielsen, L., Clements, C. S., Purcell, A. W., Brooks, A. G., Whisstock, J. C., Burrows, S. R., McCluskey, J., and Rossjohn, J. (2003) *Immunity* **18**, 53–64
44. Borbulevych, O. Y., Insaidoo, F. K., Baxter, T. K., Powell, D. J., Jr., Johnson, L. A., Restifo, N. P., and Baker, B. M. (2007) *J. Mol. Biol.* **372**, 1123–1136
45. Valmori, D., Dutoit, V., Liénard, D., Lejeune, F., Speiser, D., Rimoldi, D., Cerundolo, V., Dietrich, P. Y., Cerottini, J. C., and Romero, P. (2000) *J. Immunol.* **165**, 533–538
46. Turner, S. J., Doherty, P. C., McCluskey, J., and Rossjohn, J. (2006) *Nat. Rev. Immunol.* **6**, 883–894
47. Yoshioka, T., Matsutani, T., Iwagami, S., Tsuruta, Y., Kaneshige, T., Toyosaki, T., and Suzuki, R. (1997) *J. Immunol. Methods* **201**, 145–155
48. Tynan, F. E., Burrows, S. R., Buckle, A. M., Clements, C. S., Borg, N. A., Miles, J. J., Beddoe, T., Whisstock, J. C., Wilce, M. C., Silins, S. L., Burrows, J. M., Kjer-Nielsen, L., Kostenko, L., Purcell, A. W., McCluskey, J., and Rossjohn, J. (2005) *Nat. Immunol.* **6**, 1114–1122
49. Armstrong, K. M., Insaidoo, F. K., and Baker, B. M. (2008) *J. Mol. Recognit.* **21**, 275–287
50. Miles, J. J., Silins, S. L., and Burrows, S. R. (2006) *Curr. Med. Chem.* **13**, 2725–2736